drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous anti‑CD19 CAR T‑cell therapy with a 4‑1BB co‑stimulatory domain and CD3ζ signaling, engineered to recognize and kill CD19‑positive B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Lisocabtagene Maraleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express an anti-CD19 chimeric antigen receptor with a 4-1BB co-stimulatory domain and CD3ζ signaling; upon binding CD19 on B cells, they activate, proliferate, and mediate cytotoxic killing of CD19-positive malignant B cells.
drug_name
Lisocabtagene Maraleucel (liso‑cel)
nct_id_drug_ref
NCT06458439